GILD Gilead Sciences

Q1 2025 10-Q

Filed: May 7, 2025Period ending Mar 31, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Gilead Sciences (GILD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 7, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New regulatory risk: FDA boxed warning on CAR T therapies for secondary T-cell malignancies effective January 2024
• Updated product commercialization risk: Phase 3 EVOKE-01 trial failed in January 2024, causing impairment charge impacting pipeline valuation

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$6.7B

Net Income

$1.3B

Operating Margin

33.6%

Net Margin

19.7%

Source: XBRL data from Gilead Sciences Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Gilead Sciences Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.